UCB Adds Hidradenitis Suppurativa as Fifth Indication for Bimzelx

The U.S. FDA has expanded the label for UCB SA’s Bimzelx (bimekizumab-bkzx) to include hidradenitis suppurativa (HS), a chronic skin disease characterized by painful, boil-like lumps under the skin. This approval marks the fifth indication for Bimzelx, which is a humanized IL-17A and IL-17F antagonist. The drug is now cleared for use in adults suffering from moderate to severe HS, offering a new treatment option for those affected by this challenging condition.